New antituberculous drugs in development

Current HIV/AIDS Reports

Volumn 7, Issue 3, 2010, Pages 143-151

  Lalloo, Umesh G ^a,b   Ambaram, Anish ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Diarylquinolines; Drug resistant tuberculosis; Extensively drug resistant tuberculosis; Fluoroquinolones; HIV; Multidrug resistant tuberculosis; New antituberculosis drugs; Rifamycins

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AZD 5847; BCG VACCINE; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSERINE; ENVIOMYCIN; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NEOMYCIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFALAZIL; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIOMYCIN; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNIZATION; LEUKOPENIA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NANOTECHNOLOGY; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; COMPLICATION; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROBIOLOGY; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; FLUOROQUINOLONES; HIV INFECTIONS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 77955980346     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-010-0054-4     Document Type: Review

References (72)

1. Lalloo UG, Pillay S: Managing tuberculosis and HIV in sub- Sahara Africa. Curr HIV/AIDS Rep 2008, 5:132-139. This is a recommended review outlining the challenges related to TB and HIV in sub-Saharan Africa.
2. Lalloo UG, Naidoo R, Ambaram A: Recent advances in the medical and surgical treatment of multi-drug resistant tuberculosis.Curr Opin Pulm Med 2006, 3:179-185.
3. Gandhi NR, Shah NS, Andrews JR, et al.; Tugela Ferry Care and Research (TF CARES) Collaboration: HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010, 181:80-86. These are current data showing high mortality from drugresistant TB in a rural setting.
4. Chambers HF, Turner J, Schecter GF, et al.: Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother 2005, 49:2816-2821.
5. Chambers HF, Kocagoz T, Sipit T, et al.: Activity of amoxicillin/ clavulanate in patients with tuberculosis. Clin Infect Dis 1998, 26:874-877.
6. Donald PR, Sirgel FA, Venter A, et al.: Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis. Scand J Infect Dis 2001, 33:466-469.
7. Jagannath C, Reddy MV, Kailasam S, et al.: Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med 1995, 151:1083-1086.
8. Adams LM, Sinha I, Franzblau SG, et al.: Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. Antimicrob Agents Chemother 1999, 43:1638-1643.
9. Janulionis E, Sofer C, Song HY, Wallis RS: Lack of activity of orally administered clofazimine against intracellular Mycobacterium tuberculosis in whole-blood culture. Antimicrob Agents Chemother 2004, 48:3133-3135.
10. Shubin H, Sherson J, Pennes E, et al.: Prochlorperazine (Compazine) as an aid in the treatment of pulmonary tuberculosis.Antibiotic Med Clin Ther 1958, 5:305-309.
11. Wayne LG, Sramek HA: Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994, 38:2054-2058.
12. Fox W, Ellard GA, Mitchison DA: Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units 1946-1986 with relevant subsequent publications.Int J Tuberc Lung Dis 1999, 3:s231-s279.
13. Fox W: Whither short-course chemotherapy? Br J Dis Chest 1981, 75:331-357.
14. Schmitz P, Kleine-Allekotte B: Treatment of pulmonary tuberculosis with PAS infusions associated with INH and streptomycin.Med Welt 1960, 42:2206.
15. World Health Organization: Treatment of Tuberculosis: Guidelines for National Programmes. WHO/HTM/TB/2009.420: 2009.This is a recommended resource for TB programs.
16. Ma Z, Lienhardt C: Toward an optimized therapy for tuberculosis? Drugs in clinical trials and preclinical development. Clin Chest Med 2009, 30:755-768.
17. Protopopova M, Bogatcheva E, Nikonenko B, et al.: In search of new cures for tuberculosis. Med Chem 2007, 3:301-316. This is an excellent contemporary review of strategies for antituberculous drug development. It provides the literature evidence of the five new drugs that entered clinical trials in the past 5 years.
18. O'brien RJ, Spigelman M: New drugs for tuberculosis: current status and future prospects. Clin Chest Med 2005, 26:327-340.
19. Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors.Centre for Disease Control and Prevention. Morb Mort Wkly Rep 2000, 49:185-189.
20. Centers for Disease Control and Prevention: Notice to readers.Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. Morb Mort Wkly Report 2002, 51:214-215.
21. Dietze R, Teixeira L, Rocha LM, et al.: Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis.Antimicrob Agents Chemother 2001, 45:1972-1976.
22. Lounis N, Roscigno G: In vitro and in vivo activities of new rifamycin derivatives against mycobacterial infections. Curr Pharm Des 2004, 10:3229-3238.
23. Collins CH, Uttley AH: In-vitro susceptibility of mycobacteria to ciprofloxacin. J Antimicrob Chemother 1985, 16:575-580.
24. Berlin OG, Young LS, Bruckner DA: In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis. J Antimicrob Chemother 1987, 19:611-615.
25. Crowle AJ, Elkins N, May MH: Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages.Am Rev Respir Dis 1988, 137:1141-1146.
26. Ruiz-Serrano MJ, Alcalá L, Martínez L: In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 2000, 44:2567-2568.
27. Tomioka H. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr Pharm Des 2006, 12:4047-4070.
28. Jacobs MR: Fluoroquinolones as chemotherapeutics against mycobacterial infections. Curr Pharm Des 2004, 10:3213-3220.
29. Lewin CS, Howard BM, Smith JT: 4-Quinolone interactions with gyrase subunit B inhibitors. J Med Microbiol 1991, 35:358-362.
30. Willmott CJ, Critchlow SE, Eperon IC: The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase. J Mol Biol 1994, 242:351-363.
31. Tuberculous Research Center: Shortening short course chemotherapy.A randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian J Tuberc 2002, 49:27-38.
32. Hu Y, Coates AR, Mitchison DA: Sterilizing activities of fluoroquinolones against rifampin tolerant population of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003, 47:653-657.
33. Neuremberger EL, Yoshimatsu T, Tyagi S, et al.: Moxifloxacincontaining regimen greatly reduces time to culture conversion in murine tuberculosis. AmJ Respir Crit Care Med 2004, 169:334-335.
34. Velerio G, Braccciale P, Manisco V, et al.: Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother 2003, 15:66-70.
35. Conde MB, Efron A, Loredo C, et al.: Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009, 373:1183-1189.
36. Ginsberg AS, Grosset JH, Bishai WR: Fluoroquinolones, tuberculosis and resistance. Lancet Infect Dis 2003, 3:432-442.
37. Ziganshina LE, Vizel AA, Squire SB: Fluoroquinolones for treating tuberculosis. Cochrane Database Sys Rev 2005, 3: CD004795.
38. Andries K, Verhasselt P, Guillemont J, et al.: A diarlyquinoline drug active on the ATP synthase of mycobacterium tuberculosis.Science 2005, 307:223-227.
39. Sosnik A, Carcaboso AM, Glisoni RJ: New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev 2010, 62:547-559. This article overviews the state-of-the-art in the development of nano-based drug delivery systems.
40. Diacon AH, Pym A, Grobusch M, et al.: The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009, 360:2397-2405. This is a landmark study on TMC207.
41. Huitric E, Verhasselt P, Koul A: Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2010, 54:1022-1028.
42. Stover CK, Warrener P, VanDevanter D, et al.: A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.Nature 2000, 405:962-966.
43. Manjunatha U, Boshoff HI, Barry CE: The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol 2009, 2:215-218.
44. Martino L: Global alliance for TB drug development. In Materials for the 37th Union World Conference on Lung Health. Recent Advances in TB Drug Development: 2006.
45. Rivers EC, Mancera RL: New anti-tuberculosis drugs with novel mechanisms of action. Curr Med Chem 2008, 15:1956-1967.
46. Nikonenko BV, Protopopova M, Samala R: Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs.Antimicrob Agents Chemother 2007, 51:1563-1565.
47. Onajole OK, Govender P, van Helden PD: Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates. Eur J Med Chem 2010, 45:2075-2079.
48. Park IN, Hong SB, Oh YM, et al.: Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrugresistant tuberculosis. J Antimicrob Chemother 2006, 58:701-704.
49. Fortun J, Martin-Davila P, Navas E, et al.: Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005, 56:180-185.
50. Wallace RJ Jr, Brown-Elliott BA, Ward SC, et al.: Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001, 45:764-767.
51. Anger HA, Dworkin F, Sharma S: Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-2006. J Antimicrob Chemother 2010, 65:775-783.
52. Ntziora F, Falagas ME: Linezolid for the treatment of patients with mycobacterial infections : a systematic review. Int J Tuberc Lung Dis 2007, 11:606-611. Erratum in Int J Tuberc Lung Dis 2007, 11:936.
53. Zhang Y: Advances in the treatment of tuberculosis. Clin Pharmacol Ther 2007, 82:595-600.
54. Working group on new TB drugs. http://www.newtbdrugs.org/pipeline.php Accessed May 2010.
55. Koup JR, Williams-Warren J, Viswanathan CT, et al.: Pharmacokinetics of rifampin in children. II. Oral bioavailability. Ther Drug Monit 1986, 8:17-22.
56. Muttil P, Wang C, Hickey AJ: Inhaled drug delivery for tuberculosis therapy. Pharm Res 2009, 26:2401-2416.
57. Martineau AR, Wilkinson RJ, Wilkinson KA, et al.: A single dose of vitamin D enhances immunity to Mycobacteria. Am J Respir Crit Care Med 2007, 176:208.
58. Nnoaham KE, Clarke A: Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol 2008, 37:113-119.
59. Young JMD: Cod liver oil in phthisis. Am J Med Sci 1849, 17:235-237.
60. Spector SA: Vitamin D earns more than a passing grade. J Infect Dis 2009, 7:1015-1017.
61. Davies PD: A possible link between vitamin D deficiency and impaired host defence to Mycobacterium tuberculosis. Tubercle 1985, 66:301-306.
62. Rook GA, Steele J, Fraher L, et al.: Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 1986, 57:159-163.
63. Crowle AJ, Ross EJ, May MH: Inhibition by l,25(OH)2- vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages. Infect Immun 1987, 55:2945-2950.
64. Bellamy R, Ruwende C, Corrah T, et al.: Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J Infect Dis 1998, 179:721-724.
65. Wilkinson R, Llewelyn M, Toossi Z, et al.: Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study.Lancet 2000, 355:618-621.
66. Brodie MJ, Boobis AR, Hillyard CJ, et al.: Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity. Clin Pharmacol Ther 1981, 30:363-367.
67. Brodie MJ, Boobis AR, Hillyard CJ, et al.: Effect of rifampicin and isoniazid on vitamin D metabolism. Clin Pharmacol Ther 1982, 32:525-530.
68. Perry W, Erooga MA, Brown J, Stamp TC: Calcium metabolism during rifampicin and isoniazid therapy for tuberculosis. J R Soc Med 1982, 75:533-536.
69. Williams SE, Wardman AG, Taylor GA, et al.: Long term study of the effect of rifampicin and isoniazid on vitamin D metabolism.Tubercle 1985, 66:49-54.
70. Condos R, Rom WN, Schluger NW: Treatment of multidrugresistant tuberculosis with interferon-[gamma] via aerosol. Lancet Infect Dis 1997, 349:1513-1515.
71. McShane H, Pathan AA, Sander CR, et al.: Recombinant modified vaccinia virus Ankara expressing Antigen 85 A boosts BCG primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004, 10:1240-1244.
72. Stanford J, Stanford C, Grange J: Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front Biosci 2004, 9:1701-1719. This is recommended for readers interested in immunotherapy.